标题：The effect of pitavastatin calcium on endothelial dysfunction induced by hypercholesterolemia.
作者：Yan HM;Zhao J;Ma DZ;Wang H;Wang J;Wang ZH;Li L;Zhang Y;Zhang W;Zhong M
作者机构：[Yan, H.-M] Qilu Hospital, Shandong University, Department of Cardiology, No. 107 Wenhua West Road, Jinan, 250012, China;[ Zhao, J] Qilu Hospital, Sha 更多
通讯作者地址：[Zhong, M]Shandong Univ, Qilu Hosp, Dept Cardiol, 107 Wenhua W Rd, Jinan 250012, Peoples R China.
来源：Expert opinion on pharmacotherapy
关键词：endothelial function; hypercholesterolemia; oxidative stress;; pitavastatin calcium
摘要：OBJECTIVE: To investigate whether endothelial function can be improved by the treatment of pitavastatin calcium via its antioxidant properties in hypercholesteremia patients. METHODS: Forty patients with hypercholesteremia were randomized to receive pitavastatin calcium 1 or 2 mg/day for 8 weeks. Among them, four people were lost in the follow-up period. Before and after treatment, clinical and biochemical characteristics, markers of oxidative stress (plasma 8-iso-prostaglandin F(2alpha) and serum gp91phox) were determined and concomitantly endothelium-dependent brachial artery flow-mediated dilation (FMD) was measured by ultrasound examination. Thirty healthy subjects were chosen as controls. RESULTS: For individuals with hypercholesteremia, total cholesterol, low-density lipoprotein cholesterol (LDL-C) and serum gp91phox were significantly increased (p<0.001 for all) and plasma 8-iso-prostaglandinF2alpha (8-iso-PGF2alpha) was significantly higher (p<0.05), while FMD was obviously impaired (p<0.001). Total cholesterol, LDL-C and serum gp91phox were significantly reduced (p<0.001 for all), plasma 8-iso-PGF2alpha was lower and FMD was significantly improved after pitavastatin calcium treatment compared with those before treatment in any group (p<0.05 for both). However, there was no significant difference between the 1-mg and 2-mg pitavastatin calcium groups post-therapy. CONCLUSIONS: Endothelial dysfunction induced by hypercholesteremia can be ameliorated by pitavastatin calcium treatment, which occurs in part through its antioxidative properties.